ストックスクリーナーアプリを入手
15.35
0.06%
-0.05
Travere Therapeutics Inc (TVTX) 最新ニュース
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress - BioSpace
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress | TVTX Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.TVTX - PR Newswire
2025-06-01 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach Out | NDAQ:TVTX | Press Release - Stockhouse
Levi & Korsinsky Launches Fraud Investigation on Behalf of Travere Therapeutics, Inc. (TVTX) Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Would Travere Therapeutics (NASDAQ:TVTX) Be Better Off With Less Debt? - simplywall.st
Lost Money on Travere Therapeutics, Inc. (TVTX)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect - ACCESS Newswire
FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach | DelveInsight - The Malaysian Reserve
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Cystinuria Pipeline 2025: Groundbreaking Clinical - openPR.com
Where are the Opportunities in (TVTX) - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Ameriprise Financial Inc. Purchases 162,649 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
2025-05-23 | Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation | NDAQ:TVTX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect - ACCESS Newswire
2025-05-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect | NDAQ:TVTX | Press Release - Stockhouse
Travere Therapeutics: Establishing A Position After Last Week's Selloff (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics’ SWOT analysis: stock outlook amid regulatory review By Investing.com - Investing.com Nigeria
Travere Therapeutics’ SWOT analysis: stock outlook amid regulatory review - Investing.com
Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down – Should You Sell? - Defense World
Travere Therapeutics (NASDAQ:TVTX) Earns Outperform Rating from Wedbush - Defense World
The Manufacturers Life Insurance Company Reduces Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Stifel maintains hold on Travere stock amid FDA review delay By Investing.com - Investing.com South Africa
Travere Therapeutics Holds Annual Meeting, Elects Directors - TipRanks
The Plot Twist That Caused IBD 50's 10th Seed To Plummet - Investor's Business Daily
Travere Therapeutics stock falls on FDA review setback By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) Receives Outperform Rating from Wedb - GuruFocus
Travere Therapeutics (TVTX) Moves Forward with FILSPARI FDA Review | TVTX Stock News - GuruFocus
Travere Therapeutics (TVTX) Receives Outperform Rating from Wedbush | TVTX Stock News - GuruFocus
Travere flops as FDA accepts Filspari sNDA but plans AdCom - The Pharma Letter
Travere Therapeutics (TVTX) Receives a Buy from Bank of America Securities - The Globe and Mail
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why - inkl
Travere Therapeutics' FDA Application Accepted for Filspari in Rare Kidney Disease - marketscreener.com
Cantor Fitzgerald maintains overweight on Travere Therapeutics stock - Investing.com
Travere (TVTX) Shares Drop as FDA Declines Priority Review | TVT - GuruFocus
Travere Therapeutics (TVTX) Sees Buying Opportunity Amid Review Timeline News | TVTX Stock News - GuruFocus
Northern Trust Corp Has $13.14 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries - NewsBreak: Local News & Alerts
Travere Therapeutics’ sNDA for FILSPARI accepted by FDA - Investing.com Nigeria
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS - BioSpace
Travere stock falls on FDA AdCom for Filspari approval (TVTX) - Seeking Alpha
Travere Therapeutics (TVTX) Moves Forward with FILSPARI FDA Revi - GuruFocus
Travere Therapeutics’ FDA Acceptance for FILSPARI Application - TipRanks
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS | TVTX Stock News - GuruFocus
(TVTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Transcript : Travere Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News - GuruFocus
IgA Nephropathy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals - The Globe and Mail
0.87%
0.19%
大文字化:
|
ボリューム (24 時間):